Results 71 to 80 of about 8,267 (256)
A four-month gatifloxacin-containing regimen for treating tuberculosis. [PDF]
, 2014 BACKGROUND: Shortening the course of treatment for tuberculosis would be a major improvement for case management and disease control. This phase 3 trial assessed the efficacy and safety of a 4-month gatifloxacin-containing regimen for treating rifampin ...
Amukoye, Evans +19 more
core +1 more source
The Concise Guide to PHARMACOLOGY 2025/26: Enzymes
British Journal of Pharmacology, Volume 182, Issue S1, Page S307-S403, December 2025.The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander +31 more
wiley +1 more source
Etiology and Management of Sexual Dysfunction [PDF]
, 2009 Sexual dysfunction is the impairment or disruption of any of the three phases of normal sexual functioning, including loss of libido, impairment of physiological arousal and loss, delay or alteration of orgasm.
Bevinahalli Nanjegowda, Raveesh +5 more
core +2 more sources
Treatment of bulimia nervosa: a synthesis of evidence [PDF]
, 1999 Psychological treatments, mainly cognitive behavior therapy (CBT), and the use of antidepressant medications are the modalities of treatment that have received the most empirical support in controlled studies.
Bacaltchuk, Josué, Hay, Phillipa
core +1 more source
The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies
Obesity Reviews, Volume 26, Issue 12, December 2025.ABSTRACT Obesity is a chronic metabolic disease characterized by disturbances in energy homeostasis, leading to excessive fat accumulation. The pathogenesis of the disease is shaped by a complex interplay of genetic, epigenetic, biological, psychological, and environmental factors.
Gašper Tonin +6 more
wiley +1 more source
Clinical Pharmacology: Advances and Applications, 2020 Hinz M, Stein A, Cole T, Ryan P. Clin Pharmacol Adv Appl. 2014;6:107– 110. The Editor-in-Chief and Publisher of Clinical Pharmacology: Advances and Applications wish to issue an Expression of Concern for the published article ...
Hinz M, Stein A, Cole T, Ryan P
doaj
Phenelzine: An old drug that may hold clues to the development of new neuroprotective agents
Psychiatry and Clinical Psychopharmacology, 2021 The monoamine oxidase (MAO)-inhibiting antidepressant phenelzine (PLZ) is also used in the treatment of anxiety disorders such as panic disorder and social anxiety disorder and has been shown to have neuroprotective actions in an animal model of ...
Erin M. MacKenzie +5 more
doaj
Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency
Journal of Inherited Metabolic Disease, Volume 48, Issue 6, November 2025.ABSTRACT Tyrosine hydroxylase (TH) catalyses the rate‐limiting step in dopamine biosynthesis. Autosomal recessive tyrosine hydroxylase deficiency (THD) leads to clinical phenotypes reflecting the deficiency of dopamine, norepinephrine, or epinephrine in the central nervous system (CNS), presenting along a continuous spectrum from mild to severe forms ...
Mariya Sigatullina Bondarenko +41 more
wiley +1 more source
Lithium Augmentation in Treatment‐Resistant Depression: A Qualitative Review of the Literature
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 10, Page 688-701, October 2025.ABSTRACT Depression is the leading cause of disability worldwide, affecting people of all ages. Both pharmacological and non‐pharmacological therapies are available for its treatment. However, some patients do not respond to first‐line pharmacological interventions, referred to as treatment‐resistant depression (TRD).
Angela Acero‐González +8 more
wiley +1 more source